Sugi Predict

Sugi Predict / Compounds / SCHEMBL1162293

SCHEMBL1162293

SCHEMBL1162293

CC(C)(CO)C(N)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.42
▸ ADRA2A P08913 1/20 0.42
▸ ADRA2C P18825 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ RIPK1 Q13546 1/20 0.41
▸ DPP4 P27487 2/20 0.41
▸ F2 P00734 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ AOC3 Q16853 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20746075 1.00 LMNA (0.42) LMNAADRA2AADRA2CHIF1AKDM4E
SCHEMBL4673136 0.81 TAAR1 (0.45) SLC6A2SLC6A4SLC6A3RIPK1DPP4
SCHEMBL16012043 0.81 DPP4 (0.42) LMNAADRA2AADRA2CSLC6A2SLC6A4
SCHEMBL17724595 0.80 AOC3 (0.41) AOC3
SCHEMBL17008857 0.80 PNMT (0.43) LMNASLC6A2SLC6A4AOC3
SCHEMBL4673127 0.79 DPP4 (0.41) ADRA2AADRA2CSLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL29167063 0.79 SLC6A2 (0.42) LMNAKDM4ESLC6A2SLC6A4SLC6A3
SCHEMBL27887666 0.79 CYP2C19 (0.48) LMNAADRA2AADRA2CHIF1AKDM4E
SCHEMBL8634300 0.78 RIPK1 (0.44) LMNAKDM4ESLC6A2SLC6A4SLC6A3
SCHEMBL17724578 0.78 AOC3 (0.41) SLC6A2SLC6A4AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400501-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2024-12-05 — — US disclosed
US-20220402866-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2022-12-22 — — US disclosed
US-20220402866-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF ALLERGAN, INC. 2022-12-22 — — US disclosed
US-11208377-B2 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof ALLERGAN, INC. (US) 2021-12-28 — — US disclosed
US-11208377-B2 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof ALLERGAN, INC. (US) 2021-12-28 — — US disclosed
EP-3214086-B1 SUBSTITUTED DIHYDROPYRROLOPYRAZOLE COMPOUND UBE INDUSTRIES (JP) 2021-09-22 — — EP disclosed
US-10968238-B2 Substituted dihydropyrrolopyrazole compound UBE INDUSTRIES, LTD. (JP) 2021-04-06 — — US disclosed
CN-107074887-B Substituted dihydropyrrolopyrazoles 宇部兴产株式会社 2020-12-22 — — CN disclosed
EP-3668832-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF Allergan, Inc. (US) 2020-06-24 — — EP disclosed
CN-111225900-A 3, 4-disubstituted 3-cyclobutene-1, 2-diones and their use 阿勒根公司 2020-06-02 — — CN disclosed
US-20140248357-A1 Respiratory Disease Treatment PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2014-09-04 — — US disclosed
US-8815837-B2 Respiratory disease treatment PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2014-08-26 — — US disclosed
EP-2222272-B1 Respiratory disease treatment PULMAGEN THERAPEUTICS INFLAMMATION LTD (GB) 2012-11-07 — — EP disclosed
US-20120264787-A1 Respiratory Disease Treatment PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2012-10-18 — — US disclosed
US-8236786-B2 Respiratory disease treatment PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2012-08-07 — — US disclosed
US-20110053986-A1 RESPIRATORY DISEASE TREATMENT PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2011-03-03 — — US disclosed
WO-2011015868-A1 ENANTIOMERIC RESOLUTION METHOD PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2011-02-10 — — WO disclosed
WO-2010150014-A1 5R- 5 -DEUTERATED GLITAZONES FOR RESPIRATORY DISEASE TREATMENT PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) 2010-12-29 — — WO disclosed
EP-2222272-A1 RESPIRATORY DISEASE TREATMENT Pulmagen Therapeutics (Inflammation) Limited (GB) 2010-09-01 — — EP disclosed
WO-2010015818-A1 RESPIRATORY DISEASE TREATMENT ARGENTA DISCOVERY LIMITED (GB) 2010-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400501-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF IL17A, TSLP, SSB LMNA 4769/4885ADRA2A 1974/4885ADRA2C 1016/4885
US-11208377-B2 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof IL17A, TSLP, SSB LMNA 4769/4885ADRA2A 1974/4885ADRA2C 1016/4885
US-20220402866-A1 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF IL17A, TSLP, SSB LMNA 4769/4885ADRA2A 1974/4885ADRA2C 1016/4885
US-20120264787-A1 Respiratory Disease Treatment IL5, PPARD, PPARG LMNA 2381/4885ADRA2A 330/4885ADRA2C 89/4885
US-20140248357-A1 Respiratory Disease Treatment IL5, PPARD, SLC5A1 LMNA 3084/4885ADRA2A 482/4885ADRA2C 116/4885
US-10968238-B2 Substituted dihydropyrrolopyrazole compound QDPR, CYP2D6, KCNJ11 LMNA 3034/4885ADRA2A 1583/4885ADRA2C 875/4885
US-20110053986-A1 RESPIRATORY DISEASE TREATMENT IL5, PPARD, PPARG LMNA 2381/4885ADRA2A 330/4885ADRA2C 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.